Expression of mu-opioid receptors (MORs) has not been investigated in head and neck cancer. In this study, we aimed to assess the expression of opioids receptors in laryngeal cancer, compared to adjacent non-malignant tissue.
A retrospective case series in a single academic center.
Sixty-four specimens were taken from 32 matched patients, diagnosed with laryngeal-carcinoma (20 supraglottic and 12 glottic), and were analyzed using immunohistochemical stains for MOR. All sections were examined and evaluated with a semi-quantitative analysis for staining intensity and cell count for a percentage of the positively stained cells. Survival of patients was compared based on MOR expression.
MOR staining intensity was significantly increased in laryngeal-carcinoma compared to the normal tissue adjacent to the carcinoma (P = 0.019). The percentage of stained cells in non-involved supraglottis was significantly higher compared to the non-involved glottis (P = 0.022), yet this difference was no longer found between supra- and glottic-carcinoma tissues.
MOR may play a role in the laryngeal cancer environment, as the expression in tumor cells alters from adjacent non-cancerous tissue.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Voice
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Research Data (1975-2016), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Stat Facts: Laryngeal Cancer. Surveillance, epidemiology, and end results (SEER) program. Available at: www.seer.cancer.gov. Accessed February 26, 2020.
- Global epidemiology of head and neck cancers: a continuing challenge.Oncology. 2016; 91: 13-23
- Head and Neck Cancer (Version 1.2020).2020 (Available at:)Accessed February 26, 2020)
- Five-year survival rates and time trends of laryngeal cancer in the US population.Arch Otolaryngol Head Neck Surg. 2008; 134: 370-379
- Supraglottic versus glottic laryngeal cancer: epidemiological and pathological aspects.ORL J Otorhinolaryngol Relat Spec. 1992; 54: 43-48
- Risk factors of cancer of the larynx: results of the Heidelberg case-control study.Otolaryngol Head Neck Surg. 1992; 107: 577-582
- Alcohol and laryngeal cancer: an update.Eur J Cancer Prev. 2008; 17: 116-124
- Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal cancer.Cancer. 1992; 69: 2244-2251
- Intravenous opioid drug abuse as an independent risk factor for supraglottic squamous cell carcinoma—a case-control study.Clin Otolaryngol. 2018; 43: 456-462
- Opium and risk of laryngeal cancer.Laryngoscope. 2003; 113: 1939-1943
- Radiotherapy of carcinoma of the Larynx.Ann Acad Med Singapore. 1981; 10: 307-310
- Methadone maintenance and cancer risk: an Israeli case registry study.Drug Alcohol Depend. 2011; 119: 88-92
- Functional expression of mu-opioid receptors in the human colon cancer cell line, HT-29, and their localization in human colon.Dig Dis Sci. 2008; 53: 461-466
- Increased mu-opioid receptor expression in metastatic lung cancer.Br J Anaesth. 2014; 113: i103-i108
- Association of mu-opioid receptor expression with lymph node metastasis in esophageal squamous cell carcinoma.Dis Esophagus. 2015; 28: 196-203
- Overexpression of the mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.Anesthesiology. 2012; 116: 857-867
- Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer.Cancer. 2013; 119: 4103-4110
- MOR1 expression in gastric cancer: a biomarker associated with poor outcome.CTS journal. 2012; 8: 2
- Census Data.2008 (Available at:)Accessed April 10, 2016)
- Principles for valid histopathologic scoring in research.Vet Pathol. 2013; 50: 1007-1015
- Role of the mu-opioid receptor in opioid modulation of immune function.Amino Acids. 2013; 45: 9-24
- Microvascular structure of the larynx. A scanning electron microscopic study of microcorrosion casts.Acta Otolaryngol Suppl. 1991; 486: 254-263
- Normal Anatomy, Histology and Heterotopia of the Larynx. Atlas of Ear, Nose and Throat Pathology, Volume 16 of the series Current Histopathology.1st ed. Springer, The Netherlands1990: 82-86
- Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs.Cough. 2007; 9: 3-8
- Differential beta-catenin expression between glottic and supraglottic laryngeal carcinoma.Eur Arch Otorhinolaryngol. 2010; 267: 1573-1578
- The immunohistochemical expression of p21WAF1/Cip1 and proliferating cell nuclear antigen in laryngeal squamous cell carcinomas.J Laryngol Otol. 2006; 120: 1042-1048
- Glottic versus supraglottic tumors: differential molecular profile.Eur Arch Otorhinolaryngol. 2008; 265: 79-84
- Supraglottic and glottic carcinomas: clinically and biologically distinct entities?.Eur J Cancer. 2002; 38: 1717-1723
- 75 years of opioid research: the exciting but vain quest for the Holy Grail.Br J Pharmacol. 2006; 147: S153-S162
- Chronic opioid use in patients undergoing treatment for oropharyngeal cancer.Laryngoscope. 2019; 129: 2087-2093
- Chronic opioid use following surgery for oral cavity cancer.JAMA Otolaryngol Head Neck Surg. 2017; 143: 1187-1194
Published online: March 07, 2021
Accepted: February 11, 2021
© 2021 The Voice Foundation. Published by Elsevier Inc. All rights reserved.